非侵入性评分系统在慢性乙型肝炎纤维化检测中的作用

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL Klimik Journal Pub Date : 2022-09-28 DOI:10.36519/kd.2022.4338
Emra Asfuroğlu-Kalkan Asfuroglu-Kalkan, I. Soykan
{"title":"非侵入性评分系统在慢性乙型肝炎纤维化检测中的作用","authors":"Emra Asfuroğlu-Kalkan Asfuroglu-Kalkan, I. Soykan","doi":"10.36519/kd.2022.4338","DOIUrl":null,"url":null,"abstract":"Objectives: Chronic hepatitis is a clinical and pathological condition defined by etiological, clinical, and pathological aspects, in which inflammation in the liver continues for more than six months. Hepatitis B virus is one of the most important causes of etiology. Although liver biopsy is accepted as the gold standard test, there is a need to search for an alternative method due to the risk of complications, invasiveness, and cost. Our aim in this study was; to evaluate the predictive value of calculating fibrosis four scores (FIB -4), age platelet index (API), AST ALT ratio (AAR), AST platelet ratio index (APRI), Hui score, Goteburg University cirrhosis index (GUCI) indices in relation to liver biopsy in patients with chronic hepatitis B diagnosis who have not received any treatment before.\n\nMethods: The study included treatment-naive cases who underwent liver biopsy at Ankara University School of Medicine Hospitals Gastroenterology Clinics between March 2013 and November 2017 and at Ankara City Hospital Gastroenterology Clinic between 2019-2021. Non-invasive scores of the cases were evaluated simultaneously with liver biopsy.\n\nResults: A total of 159 patients, 45 (28.3%) female and 114 (71.7%) male, were included in our study. Eight non-invasive fibrosis markers were used, including APRI, FIB-4, AAR, API, CDS, Lok, GUCI, and Hui. GUCI and Hui non-invasive fibrosis markers were numerically superior to all other parameters in differentiating mild hepatitis from severe hepatitis and patients with cirrhosis, without cirrhosis. In the comparison of area under – receiver operating characteristic (AUROC) values ​​using the Hanley-McNeal test to differentiate the cirrhosis patient from the non-cirrhosis patient, statistical superiority was found only against AAR and API (p<0.001, p<0.001).\n\nConclusion: Although many markers were found successful in our study, AUC values ​​were not significantly superior to each other, and we determined that they could not be an alternative to liver biopsy on their own.\n\nKeywords: chronic hepatitis B, fibrosis, liver","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Role of Non-Invasive Scoring Systems in Detecting Fibrosis in Chronic Hepatitis B\",\"authors\":\"Emra Asfuroğlu-Kalkan Asfuroglu-Kalkan, I. Soykan\",\"doi\":\"10.36519/kd.2022.4338\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: Chronic hepatitis is a clinical and pathological condition defined by etiological, clinical, and pathological aspects, in which inflammation in the liver continues for more than six months. Hepatitis B virus is one of the most important causes of etiology. Although liver biopsy is accepted as the gold standard test, there is a need to search for an alternative method due to the risk of complications, invasiveness, and cost. Our aim in this study was; to evaluate the predictive value of calculating fibrosis four scores (FIB -4), age platelet index (API), AST ALT ratio (AAR), AST platelet ratio index (APRI), Hui score, Goteburg University cirrhosis index (GUCI) indices in relation to liver biopsy in patients with chronic hepatitis B diagnosis who have not received any treatment before.\\n\\nMethods: The study included treatment-naive cases who underwent liver biopsy at Ankara University School of Medicine Hospitals Gastroenterology Clinics between March 2013 and November 2017 and at Ankara City Hospital Gastroenterology Clinic between 2019-2021. Non-invasive scores of the cases were evaluated simultaneously with liver biopsy.\\n\\nResults: A total of 159 patients, 45 (28.3%) female and 114 (71.7%) male, were included in our study. Eight non-invasive fibrosis markers were used, including APRI, FIB-4, AAR, API, CDS, Lok, GUCI, and Hui. GUCI and Hui non-invasive fibrosis markers were numerically superior to all other parameters in differentiating mild hepatitis from severe hepatitis and patients with cirrhosis, without cirrhosis. In the comparison of area under – receiver operating characteristic (AUROC) values ​​using the Hanley-McNeal test to differentiate the cirrhosis patient from the non-cirrhosis patient, statistical superiority was found only against AAR and API (p<0.001, p<0.001).\\n\\nConclusion: Although many markers were found successful in our study, AUC values ​​were not significantly superior to each other, and we determined that they could not be an alternative to liver biopsy on their own.\\n\\nKeywords: chronic hepatitis B, fibrosis, liver\",\"PeriodicalId\":44309,\"journal\":{\"name\":\"Klimik Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2022-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Klimik Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36519/kd.2022.4338\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klimik Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36519/kd.2022.4338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 1

摘要

目的:慢性肝炎是一种由病因学、临床和病理方面定义的临床和病理状况,其中肝脏炎症持续6个月以上。乙型肝炎病毒是最重要的病因之一。虽然肝活检被认为是金标准检查,但由于并发症、侵入性和成本的风险,需要寻找替代方法。我们这项研究的目的是;评价计算纤维化4分(FIB -4)、年龄血小板指数(API)、AST - ALT比值(AAR)、AST -血小板比值指数(APRI)、Hui评分、哥德堡大学肝硬化指数(GUCI)对诊断为慢性乙型肝炎且此前未接受任何治疗的患者肝活检的预测价值。方法:该研究纳入了2013年3月至2017年11月在安卡拉大学医学院医院胃肠病学诊所和2019年至2021年在安卡拉市医院胃肠病学诊所接受肝脏活检的未接受治疗的病例。病例的无创评分与肝活检同时进行评估。结果:共纳入159例患者,其中女性45例(28.3%),男性114例(71.7%)。使用了8种非侵入性纤维化标志物,包括APRI、FIB-4、AAR、API、CDS、Lok、GUCI和Hui。GUCI和Hui非侵入性纤维化标志物在区分轻度肝炎和重度肝炎以及肝硬化和非肝硬化患者方面在数值上优于所有其他参数。在应用Hanley-McNeal检验区分肝硬化患者与非肝硬化患者的AUROC值比较中,只有AAR和API具有统计学优势(p<0.001, p<0.001)。结论:虽然在我们的研究中发现了许多成功的标志物,但AUC值之间并没有明显的优势,我们确定它们不能单独替代肝活检。关键词:慢性乙型肝炎,纤维化,肝脏
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Role of Non-Invasive Scoring Systems in Detecting Fibrosis in Chronic Hepatitis B
Objectives: Chronic hepatitis is a clinical and pathological condition defined by etiological, clinical, and pathological aspects, in which inflammation in the liver continues for more than six months. Hepatitis B virus is one of the most important causes of etiology. Although liver biopsy is accepted as the gold standard test, there is a need to search for an alternative method due to the risk of complications, invasiveness, and cost. Our aim in this study was; to evaluate the predictive value of calculating fibrosis four scores (FIB -4), age platelet index (API), AST ALT ratio (AAR), AST platelet ratio index (APRI), Hui score, Goteburg University cirrhosis index (GUCI) indices in relation to liver biopsy in patients with chronic hepatitis B diagnosis who have not received any treatment before. Methods: The study included treatment-naive cases who underwent liver biopsy at Ankara University School of Medicine Hospitals Gastroenterology Clinics between March 2013 and November 2017 and at Ankara City Hospital Gastroenterology Clinic between 2019-2021. Non-invasive scores of the cases were evaluated simultaneously with liver biopsy. Results: A total of 159 patients, 45 (28.3%) female and 114 (71.7%) male, were included in our study. Eight non-invasive fibrosis markers were used, including APRI, FIB-4, AAR, API, CDS, Lok, GUCI, and Hui. GUCI and Hui non-invasive fibrosis markers were numerically superior to all other parameters in differentiating mild hepatitis from severe hepatitis and patients with cirrhosis, without cirrhosis. In the comparison of area under – receiver operating characteristic (AUROC) values ​​using the Hanley-McNeal test to differentiate the cirrhosis patient from the non-cirrhosis patient, statistical superiority was found only against AAR and API (p<0.001, p<0.001). Conclusion: Although many markers were found successful in our study, AUC values ​​were not significantly superior to each other, and we determined that they could not be an alternative to liver biopsy on their own. Keywords: chronic hepatitis B, fibrosis, liver
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Klimik Journal
Klimik Journal MEDICINE, GENERAL & INTERNAL-
CiteScore
0.60
自引率
33.30%
发文量
39
期刊最新文献
Fourth-year Results of HBeAg Negative Chronic Hepatitis B Patients Discontinuing Nucleos(t)ide Analogue Therapy Trimethoprim-Sulfamethoxazole and Ciprofloxacin Resistance Rates in Escherichia coli and Klebsiella spp. in Urinary Tract Infections: A 10-Year Evaluation The Incidence and Factors Affecting the 28-day Hospital Admission Among Adult Ambulatory COVID-19 Patients Correlation of Real-Time PCR Cycle Threshold Values and Clinical Progress, Mortality, and Laboratory Parameters of COVID-19 Patients Evaluation of Risk Factors Causing Nosocomial Acinetobacter Bacteremia and Mortality in the Intensive Care Unit
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1